Lysophosphatidylcholine and lysophosphatidic acid as key messengers in atherosclerosis: from a lipid-inflammation vicious cycle to therapeutic translation - Top-Institutions - MDSpire

Lysophosphatidylcholine and lysophosphatidic acid: pivotal signaling molecules in atherosclerosis and their potential for therapeutic application

  • By

  • Xue Guan

  • Zhongyan Li

  • Huan Cheng

  • Jingru Li

  • Najie Wen

  • Luqiao Wang

  • July 21, 2026

Share

Top Institutions in Cardiology

Brief introduction explaining scope and methodology.

  • #1

    Cleveland Clinic
    Cleveland Clinic

    Cleveland, Ohio

    Key Differentiators

    • Cardiology
    • Vascular Surgery

  • #2

    University of California San Diego Health
    University of California San Diego Health

    La Jolla, California

    Key Differentiators

    • Cardiology
    • Heart Surgery

  • #3

    European Society of Cardiology
    European Society of Cardiology

    Brussels, Belgium

    Key Differentiators

    • Cardiology

  • #4

    ESC Working Group on Atherosclerosis and Vascular Biology
    ESC Working Group on Atherosclerosis and Vascular Biology

    Brussels, Belgium

    Key Differentiators

    • Cardiology

  • #5

    Million Veteran Program
    Million Veteran Program

    Washington, D.C.

    Key Differentiators

    • Cardiology

Original Source(s)

Lysophosphatidylcholine and lysophosphatidic acid as key messengers in atherosclerosis: from a lipid-inflammation vicious cycle to therapeutic translation

  • by Xue Guan, Zhongyan Li, Huan Cheng, Jingru Li, Najie Wen, Luqiao Wang

  • July 21, 2026

Related Content

Micromegaly: a distinct clinical entity? Insights from a monocentric cohort study

Predictive value of the serum sodium to log(D-dimer) ratio for the risk of all-cause death in patients with chronic heart failure with different ejection fractions

Troponin Screening and Major Cardiovascular Adverse Events During Immune Checkpoint Inhibitor Therapy